Sanginita Chemicals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Sanginita Chemicals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Chemicals earnings growth | 22.8% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Sanginita Chemicals Limited (NSE:SANGINITA) Shares Fly 26% But Investors Aren't Buying For Growth
May 01Revenues Working Against Sanginita Chemicals Limited's (NSE:SANGINITA) Share Price Following 26% Dive
Mar 11Sanginita Chemicals Limited (NSE:SANGINITA) Surges 38% Yet Its Low P/S Is No Reason For Excitement
Jan 02These 4 Measures Indicate That Sanginita Chemicals (NSE:SANGINITA) Is Using Debt Reasonably Well
Dec 30Sanginita Chemicals (NSE:SANGINITA) Seems To Use Debt Quite Sensibly
Sep 05Is Sanginita Chemicals (NSE:SANGINITA) Using Too Much Debt?
Dec 13We Think Sanginita Chemicals (NSE:SANGINITA) Is Taking Some Risk With Its Debt
Feb 15Sanginita Chemicals (NSE:SANGINITA) Has A Somewhat Strained Balance Sheet
Jul 22Is Sanginita Chemicals (NSE:SANGINITA) Using Too Much Debt?
Mar 16Sanginita Chemicals Limited's (NSE:SANGINITA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Jan 18Does Sanginita Chemicals (NSE:SANGINITA) Have A Healthy Balance Sheet?
Nov 26In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sanginita Chemicals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2024 | 2,005 | 4 | -151 | -69 | N/A |
6/30/2024 | 1,726 | 7 | N/A | N/A | N/A |
3/31/2024 | 1,515 | 8 | -62 | -23 | N/A |
12/31/2023 | 1,325 | 13 | N/A | N/A | N/A |
9/30/2023 | 1,367 | 11 | 81 | 102 | N/A |
6/30/2023 | 1,334 | 6 | N/A | N/A | N/A |
3/31/2023 | 1,486 | 4 | 128 | 137 | N/A |
12/31/2022 | 1,535 | 0 | N/A | N/A | N/A |
9/30/2022 | 1,720 | -9 | 26 | 29 | N/A |
6/30/2022 | 1,918 | -3 | N/A | N/A | N/A |
3/31/2022 | 1,981 | 3 | -36 | -30 | N/A |
12/31/2021 | 2,127 | 7 | N/A | N/A | N/A |
9/30/2021 | 1,977 | 12 | 47 | 53 | N/A |
6/30/2021 | 1,953 | 17 | N/A | N/A | N/A |
3/31/2021 | 1,648 | 8 | 82 | 85 | N/A |
12/31/2020 | 1,486 | 6 | N/A | N/A | N/A |
9/30/2020 | 1,567 | 20 | 22 | 24 | N/A |
6/30/2020 | 1,462 | 24 | N/A | N/A | N/A |
3/31/2020 | 1,598 | 34 | -24 | -16 | N/A |
12/31/2019 | 1,648 | 50 | N/A | N/A | N/A |
9/30/2019 | 1,589 | 44 | N/A | N/A | N/A |
6/30/2019 | 1,748 | 38 | N/A | N/A | N/A |
3/31/2019 | 1,876 | 39 | -3 | 6 | N/A |
3/31/2018 | 1,945 | 35 | N/A | 28 | N/A |
3/31/2017 | 1,473 | 11 | N/A | -74 | N/A |
3/31/2016 | 1,441 | 11 | N/A | 2 | N/A |
3/31/2015 | 1,286 | 10 | N/A | 23 | N/A |
3/31/2014 | 1,190 | 8 | N/A | 57 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if SANGINITA's forecast earnings growth is above the savings rate (6.7%).
Earnings vs Market: Insufficient data to determine if SANGINITA's earnings are forecast to grow faster than the Indian market
High Growth Earnings: Insufficient data to determine if SANGINITA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if SANGINITA's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if SANGINITA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SANGINITA's Return on Equity is forecast to be high in 3 years time